Pfizer Inc. (NYSE:PFE) Shares Bought by Huntleigh Advisors Inc.

Huntleigh Advisors Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 58,547 shares of the biopharmaceutical company’s stock after purchasing an additional 713 shares during the period. Huntleigh Advisors Inc.’s holdings in Pfizer were worth $1,484,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $26,000. Clarity Asset Management Inc. acquired a new position in shares of Pfizer during the 4th quarter worth approximately $27,000. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 493 shares during the last quarter. North Capital Inc. acquired a new position in Pfizer in the first quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer in the fourth quarter valued at approximately $30,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

NYSE:PFE opened at $25.45 on Friday. The firm has a market capitalization of $144.66 billion, a PE ratio of 18.44, a price-to-earnings-growth ratio of 0.92 and a beta of 0.58. The business’s fifty day moving average price is $23.67 and its 200 day moving average price is $24.84. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. Pfizer’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.82 earnings per share. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.76%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently 124.64%.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on PFE shares. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective on the stock. Redburn Atlantic decreased their price objective on Pfizer from $29.00 to $27.00 and set a “neutral” rating on the stock in a report on Wednesday, April 30th. Wolfe Research upped their price objective on Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a report on Wednesday, April 30th. Morgan Stanley boosted their target price on Pfizer from $31.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 30th. Finally, BMO Capital Markets cut their target price on Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $28.55.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.